In vitro activity of rifampin, rifabutin, rifapentine, and rifaximin against planktonic and biofilm states of staphylococci isolated from periprosthetic joint infection

Mariana Albano, Melissa J. Karau, Kerryl E. Greenwood-Quaintance, Douglas R. Osmon, Caitlin P. Oravec, Daniel J. Berry, Matthew P. Abdel, Robin Patel

Research output: Contribution to journalArticle

Abstract

The in vitro activities of rifampin, rifabutin, rifapentine, and rifaximin were tested against 200 periprosthetic joint infection (PJI)-associated staphylococci. Seven rifampin-resistant isolates had MICs of ≥4 μg/ml. Three isolates had rifampin MICs of 0.25 to 1 μg/ml and harbored an Asp471Gly RpoB variant, suggesting that the CLSI rifampin-susceptible staphylococcal breakpoint of ≤1 μg/ml may be too high. The remaining isolates had rifampin MICs of ≤0.016 μg/ml, and the rifampin, rifabutin, rifapentine, and rifaximin minimum biofilm bactericidal concentrations (MBBC) for ≥50% of isolates were 8, 1, 2, and 4 μg/ml (for S. aureus) and 2, 0.06, 0.25, and 0.5 μg/ml (for S. epidermidis), respectively, for rifampin-susceptible isolates. Nonrifampin rifamycins have promising staphylococcal activity, including antibiofilm activity.

Original languageEnglish (US)
Article numbere0095919
JournalAntimicrobial Agents and Chemotherapy
Volume63
Issue number11
DOIs
StatePublished - Jan 1 2019

Fingerprint

rifapentine
rifaximin
Rifabutin
Rifampin
Biofilms
Staphylococcus
Joints
Infection
Rifamycins
In Vitro Techniques

Keywords

  • Biofilm
  • Periprosthetic joint infection
  • Rifabutin
  • Rifampin
  • Rifamycins
  • Rifapentine
  • Rifaximin
  • RpoB
  • Staphylococcus aureus
  • Staphylococcus epidermidis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

In vitro activity of rifampin, rifabutin, rifapentine, and rifaximin against planktonic and biofilm states of staphylococci isolated from periprosthetic joint infection. / Albano, Mariana; Karau, Melissa J.; Greenwood-Quaintance, Kerryl E.; Osmon, Douglas R.; Oravec, Caitlin P.; Berry, Daniel J.; Abdel, Matthew P.; Patel, Robin.

In: Antimicrobial Agents and Chemotherapy, Vol. 63, No. 11, e0095919, 01.01.2019.

Research output: Contribution to journalArticle

Albano, Mariana ; Karau, Melissa J. ; Greenwood-Quaintance, Kerryl E. ; Osmon, Douglas R. ; Oravec, Caitlin P. ; Berry, Daniel J. ; Abdel, Matthew P. ; Patel, Robin. / In vitro activity of rifampin, rifabutin, rifapentine, and rifaximin against planktonic and biofilm states of staphylococci isolated from periprosthetic joint infection. In: Antimicrobial Agents and Chemotherapy. 2019 ; Vol. 63, No. 11.
@article{8c4f374c1ebd4983a122fb455156187b,
title = "In vitro activity of rifampin, rifabutin, rifapentine, and rifaximin against planktonic and biofilm states of staphylococci isolated from periprosthetic joint infection",
abstract = "The in vitro activities of rifampin, rifabutin, rifapentine, and rifaximin were tested against 200 periprosthetic joint infection (PJI)-associated staphylococci. Seven rifampin-resistant isolates had MICs of ≥4 μg/ml. Three isolates had rifampin MICs of 0.25 to 1 μg/ml and harbored an Asp471Gly RpoB variant, suggesting that the CLSI rifampin-susceptible staphylococcal breakpoint of ≤1 μg/ml may be too high. The remaining isolates had rifampin MICs of ≤0.016 μg/ml, and the rifampin, rifabutin, rifapentine, and rifaximin minimum biofilm bactericidal concentrations (MBBC) for ≥50{\%} of isolates were 8, 1, 2, and 4 μg/ml (for S. aureus) and 2, 0.06, 0.25, and 0.5 μg/ml (for S. epidermidis), respectively, for rifampin-susceptible isolates. Nonrifampin rifamycins have promising staphylococcal activity, including antibiofilm activity.",
keywords = "Biofilm, Periprosthetic joint infection, Rifabutin, Rifampin, Rifamycins, Rifapentine, Rifaximin, RpoB, Staphylococcus aureus, Staphylococcus epidermidis",
author = "Mariana Albano and Karau, {Melissa J.} and Greenwood-Quaintance, {Kerryl E.} and Osmon, {Douglas R.} and Oravec, {Caitlin P.} and Berry, {Daniel J.} and Abdel, {Matthew P.} and Robin Patel",
year = "2019",
month = "1",
day = "1",
doi = "10.1128/AAC.00959-19",
language = "English (US)",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - In vitro activity of rifampin, rifabutin, rifapentine, and rifaximin against planktonic and biofilm states of staphylococci isolated from periprosthetic joint infection

AU - Albano, Mariana

AU - Karau, Melissa J.

AU - Greenwood-Quaintance, Kerryl E.

AU - Osmon, Douglas R.

AU - Oravec, Caitlin P.

AU - Berry, Daniel J.

AU - Abdel, Matthew P.

AU - Patel, Robin

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The in vitro activities of rifampin, rifabutin, rifapentine, and rifaximin were tested against 200 periprosthetic joint infection (PJI)-associated staphylococci. Seven rifampin-resistant isolates had MICs of ≥4 μg/ml. Three isolates had rifampin MICs of 0.25 to 1 μg/ml and harbored an Asp471Gly RpoB variant, suggesting that the CLSI rifampin-susceptible staphylococcal breakpoint of ≤1 μg/ml may be too high. The remaining isolates had rifampin MICs of ≤0.016 μg/ml, and the rifampin, rifabutin, rifapentine, and rifaximin minimum biofilm bactericidal concentrations (MBBC) for ≥50% of isolates were 8, 1, 2, and 4 μg/ml (for S. aureus) and 2, 0.06, 0.25, and 0.5 μg/ml (for S. epidermidis), respectively, for rifampin-susceptible isolates. Nonrifampin rifamycins have promising staphylococcal activity, including antibiofilm activity.

AB - The in vitro activities of rifampin, rifabutin, rifapentine, and rifaximin were tested against 200 periprosthetic joint infection (PJI)-associated staphylococci. Seven rifampin-resistant isolates had MICs of ≥4 μg/ml. Three isolates had rifampin MICs of 0.25 to 1 μg/ml and harbored an Asp471Gly RpoB variant, suggesting that the CLSI rifampin-susceptible staphylococcal breakpoint of ≤1 μg/ml may be too high. The remaining isolates had rifampin MICs of ≤0.016 μg/ml, and the rifampin, rifabutin, rifapentine, and rifaximin minimum biofilm bactericidal concentrations (MBBC) for ≥50% of isolates were 8, 1, 2, and 4 μg/ml (for S. aureus) and 2, 0.06, 0.25, and 0.5 μg/ml (for S. epidermidis), respectively, for rifampin-susceptible isolates. Nonrifampin rifamycins have promising staphylococcal activity, including antibiofilm activity.

KW - Biofilm

KW - Periprosthetic joint infection

KW - Rifabutin

KW - Rifampin

KW - Rifamycins

KW - Rifapentine

KW - Rifaximin

KW - RpoB

KW - Staphylococcus aureus

KW - Staphylococcus epidermidis

UR - http://www.scopus.com/inward/record.url?scp=85073764348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073764348&partnerID=8YFLogxK

U2 - 10.1128/AAC.00959-19

DO - 10.1128/AAC.00959-19

M3 - Article

C2 - 31451499

AN - SCOPUS:85073764348

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

M1 - e0095919

ER -